Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

This phase 3 trial evaluated the safety and efficacy of inclisiran, a small interfering RNA that inhibits hepatic PCSK9 synthesis, in 482 adults with heterozygous familial hypercholesterolemia, who received subcutaneous injections of inclisiran or placebo on days 1, 90, 270, and 450. Changes in chol...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-04, Vol.382 (16), p.1520-1530
Hauptverfasser:	Raal, Frederick J, Kallend, David, Ray, Kausik K, Turner, Traci, Koenig, Wolfgang, Wright, R. Scott, Wijngaard, Peter L.J, Curcio, Danielle, Jaros, Mark J, Leiter, Lawrence A, Kastelein, John J.P
Format:	Artikel
Sprache:	eng
Schlagworte:	Apolipoproteins Arteriosclerosis Cardiovascular disease Cardiovascular diseases Cholesterol Confidence intervals Deoxyribonucleic acid DNA Dosage Genotypes Health risk assessment Hypercholesterolemia Immunoglobulins Kexin Low density lipoprotein Monoclonal antibodies Proprotein convertases siRNA Software Statins Subtilisin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This phase 3 trial evaluated the safety and efficacy of inclisiran, a small interfering RNA that inhibits hepatic PCSK9 synthesis, in 482 adults with heterozygous familial hypercholesterolemia, who received subcutaneous injections of inclisiran or placebo on days 1, 90, 270, and 450. Changes in cholesterol were assessed up to day 540.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1913805